For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| CohortA1:R/M HNSCC Treatment-naïve for R/M Disease:Pegenzileukin 24mcg/kg+Pembrolizumab as 1LTherapy | Participants with HNSCC who were treatment-naïve for R/M disease with PD-L1 CPS \>=1 were included in this cohort. Participants received pegenzileukin 24 mcg/kg along with pembrolizumab 200 mg via IV infusion q3w on Day 1 of each cycle (each cycle is 21 days) (as 1L therapy), until PD, unacceptable AE, other full permanent discontinuation criteria was met or completion of Cycle 35. | 8 | None | 11 | 20 | 20 | 20 | View |
| Cohort B1: R/M HNSCC: Pegenzileukin 24 mcg/kg + Pembrolizumab as 2/3L Therapy | Participants with R/M HNSCC previously treated with PD1/PD-L1-based regimen and platinum-based regimen after failure of no more than 2 regimens for R/M disease were included in this cohort. Participants received pegenzileukin 24 mcg/kg along with pembrolizumab 200 mg via IV infusion q3w on Day 1 of each cycle (each cycle is 21 days) (as 2/3L therapy), until PD, unacceptable AE, other full permanent discontinuation criteria was met or completion of Cycle 35. | 13 | None | 11 | 20 | 18 | 20 | View |
| Cohort B2: R/M HNSCC: Pegenzileukin 24 mcg/kg + Cetuximab as 2/3L Therapy | Participants with R/M HNSCC previously treated with platinum-based regimen and cetuximab-naïve after failure of no more than 2 regimens for R/M disease were included in this cohort. Participants received pegenzileukin 24 mcg/kg q3w on Day 1 of each cycle along with cetuximab as an initial loading dose of 400 mg/m\^2 on Cycle 1 Day 1 followed by 250 mg/m\^2 starting via IV infusion once weekly from Cycle 1 Day 8 (each cycle is 21 days) (as 2/3L therapy) until PD. | 10 | None | 8 | 19 | 19 | 19 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Acute Respiratory Failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Obstructive Airways Disorder | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Respiratory Failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Infusion Related Reaction | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDra 27.1 | View |
| Wound Haemorrhage | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDra 27.1 | View |
| Abscess Neck | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Atypical Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Covid-19 | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Catheter Site Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Pneumonia Aspiration | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Staphylococcal Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Wound Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Cytokine Release Syndrome | SYSTEMATIC_ASSESSMENT | Immune system disorders | MedDra 27.1 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Hypercalcaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Acute Cardiac Event | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Acute Myocardial Infarction | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Cardiac Arrest | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Cardio-Respiratory Arrest | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Pericarditis | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Capillary Leak Syndrome | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDra 27.1 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Pneumothorax | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Acute Kidney Injury | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDra 27.1 | View |
| Death | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Disease Progression | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| General Physical Health Deterioration | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Hyperthermia | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Systemic Inflammatory Response Syndrome | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Gastrostomy | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | MedDra 27.1 | View |
| Device Occlusion | SYSTEMATIC_ASSESSMENT | Product Issues | MedDra 27.1 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Bacteraemia | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Covid-19 | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Cellulitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Conjunctivitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Folliculitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Impetigo | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Localised Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Nasopharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Oral Candidiasis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Oral Herpes | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDra 27.1 | View |
| Hypothyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | MedDra 27.1 | View |
| Decreased Appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Hypokalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Hypophosphataemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDra 27.1 | View |
| Tongue Ulceration | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Cellulite | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Decubitus Ulcer | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Dermatitis Acneiform | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Dry Skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Hyperhidrosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Night Sweats | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Onycholysis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Palmar-Plantar Erythrodysaesthesia Syndrome | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Rash Maculo-Papular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Rash Vesicular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Skin Discharge | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Skin Swelling | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Skin Ulcer | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDra 27.1 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Back Pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Muscle Spasms | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Neck Pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Pathological Fracture | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDra 27.1 | View |
| Chromaturia | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDra 27.1 | View |
| Dysuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDra 27.1 | View |
| Pollakiuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDra 27.1 | View |
| Adverse Drug Reaction | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Asthenia | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Feeling Hot | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Hyperpyrexia | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Influenza Like Illness | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Mucosal Inflammation | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Oedema Peripheral | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Xerosis | SYSTEMATIC_ASSESSMENT | General disorders | MedDra 27.1 | View |
| Alanine Aminotransferase Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Aspartate Aminotransferase Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Alkaline Phosphatase Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Bilirubin Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Calcium Decreased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Glucose Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Magnesium Decreased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Phosphorus Decreased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Pressure Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Blood Thyroid Stimulating Hormone Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Weight Decreased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Weight Increased | SYSTEMATIC_ASSESSMENT | Investigations | MedDra 27.1 | View |
| Fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDra 27.1 | View |
| Infusion Related Reaction | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDra 27.1 | View |
| Paronychia | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Pneumonia Aspiration | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Post Procedural Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Respiratory Tract Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Sinusitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Urinary Tract Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDra 27.1 | View |
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDra 27.1 | View |
| Hyperleukocytosis | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDra 27.1 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDra 27.1 | View |
| Panic Attack | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDra 27.1 | View |
| Brain Fog | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Presyncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDra 27.1 | View |
| Eye Pain | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDra 27.1 | View |
| Ear Pain | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | MedDra 27.1 | View |
| Vertigo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | MedDra 27.1 | View |
| Sinus Tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | MedDra 27.1 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDra 27.1 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDra 27.1 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Dysphonia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Lung Disorder | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Nasal Inflammation | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Oropharyngeal Pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Pharyngeal Haemorrhage | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Pneumothorax | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Productive Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Rhinorrhoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDra 27.1 | View |
| Abdominal Distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Abdominal Pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Abdominal Pain Upper | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Dry Mouth | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Odynophagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Oral Dysaesthesia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Salivary Hypersecretion | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Stomatitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDra 27.1 | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDra 27.1 | View |
| Cytokine Release Syndrome | SYSTEMATIC_ASSESSMENT | Immune system disorders | MedDra 27.1 | View |
| Cell Death | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |
| Hypomagnesaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDra 27.1 | View |